73 research outputs found
Terms non-exudative and non-neovascular: awaiting entry at the doors of AMD reclassification
n/
Scleral Buckling for Primary Retinal Detachment: Outcomes of Scleral Tunnels versus Scleral Sutures
Purpose: There are primarily two techniques for affixing the scleral buckle (SB) to the sclera in the repair of rhegmatogenous retinal detachment (RRD): scleral tunnels or scleral sutures.
Methods: This retrospective study examined all patients with primary RRD who were treated with primary SB or SB combined with vitrectomy from January 1, 2015 through December 31, 2015 across six sites. Two cohorts were examined: SB affixed using scleral sutures versus scleral tunnels. Pre- and postoperative variables were evaluated including visual acuity, anatomic success, and postoperative strabismus.
Results: The mean preoperative logMAR VA for the belt loop cohort was 1.05 ± 1.06 (Snellen 20/224) and for the scleral suture cohort was 1.03 ± 1.04 (Snellen 20/214, p = 0.846). The respective mean postoperative logMAR VAs were 0.45 ± 0.55 (Snellen 20/56) and 0.46 ± 0.59 (Snellen 20/58, p = 0.574). The single surgery success rate for the tunnel cohort was 87.3% versus 88.6% for the suture cohort (p = 0.601). Three patients (1.0%) in the scleral tunnel cohort developed postoperative strabismus, but only one patient (0.1%) in the suture cohort (p = 0.04, multivariate p = 0.76). All cases of strabismus occurred in eyes that underwent SB combined with PPV (p = 0.02). There were no differences in vision, anatomic success, or strabismus between scleral tunnels versus scleral sutures in eyes that underwent primary SB.
Conclusion: Scleral tunnels and scleral sutures had similar postoperative outcomes. Combined PPV/SB in eyes with scleral tunnels might be a risk for strabismus post retinal detachment surgery
Long-Term Results from an Epiretinal Prosthesis to Restore Sight to the Blind
PurposeRetinitis pigmentosa (RP) is a group of inherited retinal degenerations leading to blindness due to photoreceptor loss. Retinitis pigmentosa is a rare disease, affecting only approximately 100 000 people in the United States. There is no cure and no approved medical therapy to slow or reverse RP. The purpose of this clinical trial was to evaluate the safety, reliability, and benefit of the Argus II Retinal Prosthesis System (Second Sight Medical Products, Inc, Sylmar, CA) in restoring some visual function to subjects completely blind from RP. We report clinical trial results at 1 and 3 years after implantation.DesignThe study is a multicenter, single-arm, prospective clinical trial.ParticipantsThere were 30 subjects in 10 centers in the United States and Europe. Subjects served as their own controls, that is, implanted eye versus fellow eye, and system on versus system off (native residual vision).MethodsThe Argus II System was implanted on and in a single eye (typically the worse-seeing eye) of blind subjects. Subjects wore glasses mounted with a small camera and a video processor that converted images into stimulation patterns sent to the electrode array on the retina.Main Outcome MeasuresThe primary outcome measures were safety (the number, seriousness, and relatedness of adverse events) and visual function, as measured by 3 computer-based, objective tests.ResultsA total of 29 of 30 subjects had functioning Argus II Systems implants 3 years after implantation. Eleven subjects experienced a total of 23 serious device- or surgery-related adverse events. All were treated with standard ophthalmic care. As a group, subjects performed significantly better with the system on than off on all visual function tests and functional vision assessments.ConclusionsThe 3-year results of the Argus II trial support the long-term safety profile and benefit of the Argus II System for patients blind from RP. Earlier results from this trial were used to gain approval of the Argus II by the Food and Drug Administration and a CE mark in Europe. The Argus II System is the first and only retinal implant to have both approvals
Baseline Predictors of Vitreomacular Adhesion/Traction Resolution Following an Intravitreal Injection of Ocriplasmin
Surgical Approaches for Cell Transplantation in Cell Replacement Therapy
Human embryonic stem cell (hESC) transplantation holds great promise as a viable treatment option for neurodegenerative diseases. Transplantation of hESCs can replace dysfunctional cells or provide trophic factors to sustain degenerating cells. Ocular conditions, particularly retinal degenerative disorders, are especially suited to hESC transplantation due to ease of accessibility and lack of immunogenicity in the subretinal space. Recently, embryonic stem cell transplantation of the retinal pigment epithelium (RPE) has been utilized in degenerative retinal conditions such as age-related macular degeneration and Stargardt’s disease, with promising results. This chapter will summarize important surgical approaches to hESC-RPE transplantation for age-related macular degeneration and Stargardt’s disease, as well discuss the future directions of cell therapy in degenerative retinal disease
Recommended from our members
Vitreoretinal Disease: Diagnosis, Management, and Clinical Pearls - 19 Macular Dystrophies
Recommended from our members
Vitreoretinal Disease: Diagnosis, Management, and Clinical Pearls - 14 Age-Related Macular Degeneration
Recommended from our members
Vitreoretinal Disease: Diagnosis, Management, and Clinical Pearls - 20 Hereditary Retinal Degenerations
Recommended from our members
Vitreoretinal Disease: Diagnosis, Management, and Clinical Pearls - 22 Retinal Manifestations of Metabolic Disease
- …